Quick Answer
IO Biotech, Inc. reported Net Income of -$95.49 million for fiscal year 2024.
IO Biotech, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$95.49M -10.9% |
-$86.08M -20.5% |
-$71.46M -5.3% |
-$67.88M -463.7% |
-$12.04M | — |
| Diluted EPS | -$1.45 +26.8% |
-$1.98 +20.2% |
-$2.48 +85.7% |
-$17.30 | — | — |
| Total Assets | $67.70M -55.1% |
$150.72M -0.7% |
$151.81M -31.7% |
$222.29M +3832.2% |
$5.65M | — |
| Cash and Equivalents | $60.03M -58.1% |
$143.19M +0.4% |
$142.59M -32.6% |
$211.53M +6112.4% |
$3.40M | — |
| Stockholders Equity | $47.02M -64.7% |
$133.16M -4.1% |
$138.85M -34.5% |
$211.92M +700.3% |
-$35.30M -50.0% |
-$23.53M |
| R&D Expense | $71.48M +5.4% |
$67.83M +44.4% |
$46.99M +55.8% |
$30.15M +256.2% |
$8.46M | — |
| Operating Income | -$95.18M -4.1% |
-$91.44M -28.0% |
-$71.42M -73.2% |
-$41.23M -306.4% |
-$10.14M | — |
| Shares Outstanding | 65.88M +0.0% |
65.88M +128.6% |
28.82M +0.0% |
28.82M | 0 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.38M | +65.1% | +68.0% |
| Diluted EPS | September 30, 2025 | -$0.13 | +63.9% | +67.5% |
| Total Assets | September 30, 2025 | $39.96M | -55.6% | -5.6% |
| Cash and Equivalents | September 30, 2025 | $30.66M | -61.8% | +9.0% |
| Long-Term Debt | September 30, 2025 | $16.66M | — | +148.0% |
| Stockholders Equity | September 30, 2025 | $911.0K | -98.7% | -42.8% |
| R&D Expense | September 30, 2025 | $13.74M | -31.9% | -17.5% |
| Operating Income | September 30, 2025 | -$19.36M | +27.0% | +16.5% |
| Shares Outstanding | September 30, 2025 | 69.69M | +5.8% | +5.8% |
- IO Biotech, Inc. reported Net Income of -$95.49 million for fiscal year 2024.
- IO Biotech, Inc. showed a decrease of -10.9% in Net Income compared to the prior fiscal year.
- IO Biotech, Inc. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2024.
- IO Biotech, Inc. showed an increase of +26.8% in Diluted EPS compared to the prior fiscal year.
- IO Biotech, Inc. reported Total Assets of $67.70 million for fiscal year 2024.
- IO Biotech, Inc. showed a decrease of -55.1% in Total Assets compared to the prior fiscal year.
- IO Biotech, Inc. reported Cash and Equivalents of $60.03 million for fiscal year 2024.
- IO Biotech, Inc. showed a decrease of -58.1% in Cash and Equivalents compared to the prior fiscal year.
- IO Biotech, Inc. reported Stockholders Equity of $47.02 million for fiscal year 2024.
- IO Biotech, Inc. showed a decrease of -64.7% in Stockholders Equity compared to the prior fiscal year.
- IO Biotech, Inc. reported R&D Expense of $71.48 million for fiscal year 2024.
- IO Biotech, Inc. showed an increase of +5.4% in R&D Expense compared to the prior fiscal year.
- IO Biotech, Inc. reported Operating Income of -$95.18 million for fiscal year 2024.
- IO Biotech, Inc. showed a decrease of -4.1% in Operating Income compared to the prior fiscal year.
- IO Biotech, Inc. reported Shares Outstanding of 65.88 million shares for fiscal year 2024.
- IO Biotech, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: